Blood Profiling Atlas in Cancer

What Blood Profiling Atlas in Cancer does

The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium is a 501(c)(3) non-profit, pre-competitive public-private consortium launched in October 2016 and operating independently since February 2017 as an operating division of the Center for Computational Science Research, Inc. (CCSR), an Illinois not-for-profit. Its stated mission is to accelerate the development, validation, and clinical use of liquid biopsy assays, premised on the founders' view that field-level bottlenecks stem from lack of collaboration rather than technology limitations.

BLOODPAC's core offerings are infrastructure- and standards-oriented rather than commercial. The BLOODPAC Data Commons (BPDC) is an open, publicly accessible repository aggregating raw and processed liquid biopsy data from retrospective and prospective member studies. The BLOODPAC Portal standardizes Minimum Technical Data Elements (MTDEs) extracted from liquid biopsy publications, enabling comparison of methods and findings across studies. Supporting assets include the BLOODPAC Dictionary (curated liquid biopsy terminology, refreshed annually), Frameworks & Standards publications, working groups spanning Data Science, MRD, Early Detection & Screening, Analytical Validation, bTMB, Brain Tumor, CHIP, Global Regulatory, Reimbursement & Policy, and Accessibility, and a library of member publications. The consortium published the first FDA-consulted Generic Protocols for Analytical Validation of NGS-based ctDNA Assays.

The business model is member-driven and member-funded: annual membership dues from ~88-94 industry, academic, government, and non-profit partners (segment mix: 43% diagnostic/industry, 29% academic/non-profit, 13% pharma, 4% government, balance other) support a small full-time staff (~5 people) and core programs. There is no commercial product sales; customers in the traditional sense are sponsors/members rather than buyers, and engagement occurs through working group participation, quarterly meetings, an annual summit, and working group deliverables. Named members include Guardant Health, GRAIL, Adaptive Biotechnologies, AstraZeneca, Bristol Myers Squibb, Pfizer, Foundation Medicine, Quest Diagnostics, Labcorp, Memorial Sloan Kettering, USC, the U.S. FDA, NCI, FNIH, Friends of Cancer Research, and AACR. Geographic footprint is global with named activities in North America and Europe.

Name

Blood Profiling Atlas in Cancer

Legal name

Center for Computational Science Research, Inc.

Website

https://bloodpac.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

The Blood Profiling Atlas in Cancer (BLOODPAC) is a non-profit 501(c)(3) consortium that builds pre-competitive data infrastructure, validation protocols, and standards for liquid biopsy through 88+ industry, academic, and government member organizations.

Ownership category

akta.pro rank

Product category

Liquid Biopsy Research Data Infrastructure

NAICS

Voluntary Health Organizations (813212), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Data Management, Reporting & Regulatory Submissions for Central Labs (HLAGAEAL)

akta.pro secondary industries

Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL)

Keywords

• Liquid biopsy research
• CtDNA assay validation
• Oncology data commons
• Pre-competitive consortium
• Clinical biomarker standards

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Annual Membership Dues: BLOODPAC is a member-driven and member-funded organization. Annual membership dues from industry, academic, and government partners support BLOODPAC's staff, infrastructure, development and maintenance of the BLOODPAC Portal, and funding for core programs and publications.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

BLOODPAC operates a pre-competitive public-private consortium that provides collaborative research infrastructure for liquid biopsy assay development, validation, and clinical implementation. The consortium delivers the BLOODPAC Data Commons (BPDC), an open data repository for sharing raw and processed liquid biopsy datasets, and the BLOODPAC Portal, a centralized resource that organizes and standardizes data elements extracted from liquid biopsy publications. Supporting offerings include standardized analytical validation protocols developed with the FDA, a curated terminology dictionary, frameworks and standards publications, and member working groups focused on regulatory science, reimbursement, and clinical adoption.

Product overview

BLOODPAC is a pre-competitive public-private consortium, not a traditional product company. The organization offers a platform of collaborative resources centered around three core offerings: the BLOODPAC Portal (a data organization and publication platform), the BLOODPAC Data Commons (an open data repository), and various Working Groups (collaborative programs addressing standards, validation protocols, and regulatory science). Additional resources include the BLOODPAC Dictionary (terminology standards), Frameworks & Standards publications, and Member Publications. The consortium's value proposition lies in fostering collaboration, data sharing, and evidence generation to advance liquid biopsy assays toward regulatory acceptance and clinical utility.

Differentiator

Problem solved

Functional benefit

Products and services

• BLOODPAC Portal A centralized web resource that organizes and standardizes data from liquid biopsy publications by extracting and structuring Minimum Technical Data Elements (MTDEs) across studies, enabling researchers to submit publications for curation and explore structured data to identify trends and generate insights.
• BLOODPAC Data Commons (BPDC) An open, publicly accessible data commons for the global liquid biopsy community that supports exchange of raw and processed data generated by liquid biopsy research, aggregating datasets from retrospective basic, clinical, and regulatory member studies, as well as prospectively organized projects.
• BLOODPAC Dictionary A curated lexicon of liquid biopsy terminology reviewed annually to ensure definitions remain current and accurate for the community, providing standardized language across the consortium's data, publications, and working groups.
• Frameworks & Standards Publications and guidelines establishing consensus frameworks and best practices for liquid biopsy assay development, validation, and clinical implementation, including analytical validation protocols and consensus documents from working groups.
• Member Publications A compilation of peer-reviewed publications from BLOODPAC members documenting research findings in liquid biopsy technology and applications, including joint studies on ctDNA analysis, MRD, early detection, and companion diagnostics.
• Working Groups Collaborative programs that convene consortium members to address key industry challenges, including Data Science, MRD, Early Detection & Screening, Analytical Validation, bTMB, Brain Tumor, CHIP, Global Regulatory, Reimbursement & Policy, and Accessibility working groups.

Quantifiable outcome

• 88+ industry, academic, and government partners collaborating through working groups
• +1 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

16 partnerships are on record, tiered core, major and supporting.

• Center for Computational Science Research, Inc. (CCSR)coreStrategic or Co-development PartnerBLOODPAC is organized as an independent operating division of CCSR, a 501(c)(3) not-for-profit Illinois corporation. CCSR was founded in 2008 and hosts other independent consortia including the Data Mining Group, Open Commons Consortium, and Pandemic Response Consortium.
• U.S. Food & Drug Administration (FDA)coreStrategic or Co-development PartnerFDA collaborated on development of analytical validation protocols for NGS-based ctDNA assays. BLOODPAC regularly engages with FDA's Center for Devices and Radiologic Health (CDRH) and is developing global regulatory standards for liquid biopsy diagnostics.
• National Cancer Institute (NCI) / Cancer Biomarkers Research GroupcoreStrategic or Co-development PartnerNCI research group collaborates as government agency member, contributing to working groups and consortium activities for liquid biopsy standards development.
• Friends of Cancer ResearchmajorStrategic or Co-development PartnerNon-profit collaborator on bTMB Analytical Validation Working Group, supporting development of best practices for validating blood-based tumor mutational burden tests.
• Foundation for the National Institutes of Health (FNIH)majorStrategic or Co-development PartnerCollaborator listed among consortium members, supporting pre-competitive liquid biopsy research initiatives.
• American Association for Cancer Research (AACR)majorGTM or Marketing PartnerCollaboration on educational sessions at AACR Annual Meeting, including ED&S Working Group session on cancer risk and risk assessment for liquid biopsy-based screening.
• Guardant HealthmajorStrategic or Co-development PartnerConsortium member contributing scientific expertise. CTO Darya Chudova serves on Scientific Co-Chair Committee. Multiple joint publications on ctDNA analysis and clinical utility.
• Bristol Myers SquibbmajorStrategic or Co-development PartnerConsortium member with Executive Director Jonathan Baden serving on Scientific Co-Chair Committee. Multiple publications on ctDNA markers in cancer.
• GRAILmajorStrategic or Co-development PartnerConsortium member focused on multi-cancer early detection. Contributing to ED&S Working Group discussions on risk assessment and terminology for MCD tests.
• Foundation MedicinemajorStrategic or Co-development PartnerConsortium member with VP Regulatory Policy Elizabeth Mansfield serving on Scientific Co-Chair Committee. Multiple publications on ctDNA genomic profiling.
• University of Southern CaliforniamajorStrategic or Co-development PartnerAcademic member with Professor Peter Kuhn on Executive Committee. Houses High Definition Single Cell Assay discovery platform and contributes extensive research on CTCs and liquid biopsy.
• Memorial Sloan Kettering Cancer CentermajorStrategic or Co-development PartnerAcademic consortium member contributing to working groups. Research publications on liquid biopsy applications in prostate cancer and brain tumors.
• International Society of Liquid Biopsy (ISLB)majorStrategic or Co-development PartnerProfessional society member collaborating on educational initiatives and annual meeting programming for liquid biopsy community.
• Prostate Cancer Clinical Trials Consortium (PCCTC)coreStrategic or Co-development PartnerStrategic collaborator with CEO Jake Vinson serving on BLOODPAC Executive Committee. Focus on accelerating clinical trials for prostate cancer liquid biopsy applications.
• StrecksupportingStrategic or Co-development PartnerDiagnostic industry member and meeting host. Hosts Q3 2023 consortium meeting in Omaha, Nebraska. Contributes to working group activities.
• PersonalissupportingStrategic or Co-development PartnerDiagnostic company member and Q3 2024 meeting host in Fremont, CA. Contributes to working groups on data standards and analytical validation.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Others

• Accelerate Diagnostics (Accelerate Pheno): Diagnostics company developing rapid identification and antimicrobial susceptibility testing platforms. Not a direct competitor, but represents the broader diagnostic industry ecosystem that BLOODPAC's protocols help standardize, providing a reference point for the membership base BLOODPAC serves.
• Translational Genomics Research Institute (TGen): Non-profit genomics research institute that conducts translational research and operates clinical sequencing/biomarker programs. Not a consortium but a comparable non-profit biomedical research entity contributing to the liquid biopsy ecosystem through academic research and data generation.
• Open Commons Consortium:

Direct peers

• Critical Path Institute (C-Path): Independent non-profit that builds pre-competitive public-private consortia (e.g., in Alzheimer's, Parkinson's, TB) to develop data standards, regulatory tools, and qualification dossiers with FDA/EMA. Operates the same consortium model as BLOODPAC but across multiple therapeutic areas, with analogous governance, membership dues, and regulatory engagement focus.
• Foundation for the National Institutes of Health (FNIH): Non-profit that convenes public-private partnerships (most notably the Biomarkers Consortium) to advance biomedical research through shared data, standards, and clinical studies. Functions as both a BLOODPAC member/collaborator and a structural twin running parallel pre-competitive consortia with FDA engagement.
• Friends of Cancer Research: Non-profit advocacy and research organization that drives collaborations among patient advocates, researchers, regulators, and industry to accelerate cancer therapy development. Collaborates with BLOODPAC on bTMB analytical validation working groups and shares the same federal-regulatory convening function.
• Clinical Trials Transformation Initiative (CTTI): Public-private partnership co-founded by Duke University and FDA that develops evidence-based recommendations to improve clinical trial design, conduct, and oversight. Mirrors BLOODPAC's pre-competitive model, member-driven governance, and emphasis on translating working group output into FDA-accepted best practices.
• Medical Device Innovation Consortium (MDIC): Public-private partnership that brings together regulators, industry, nonprofits, and patient organizations to advance medical device regulatory science. Operates working groups, frameworks, and data resources similar to BLOODPAC's, but with a device rather than liquid biopsy diagnostics focus.
• Pandemic Response Consortium: Independent consortium also housed under CCSR that mobilizes pre-competitive data sharing and analytics across institutions during health emergencies. Closely analogous in operating model, governance, and parent organization to BLOODPAC, but applied to infectious disease rather than oncology.

Emerging players

• International Society of Liquid Biopsy (ISLB): Professional society that hosts annual meetings and educational programming for the liquid biopsy community and collaborates with BLOODPAC on events. Adjacent rather than directly competitive, but plays a complementary convening role in the same scientific community.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/blood_pac
• LinkedInlinkedin.com/company/blood-profiling-atlas-in-cancer-bloodpac

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blood Profiling Atlas in Cancer